On March 13, 2024, Absolute Pure EnviroSci Limited (“APEL”) Biomedical Technology Innovation and Translational Commercial Laboratory was inaugurated at Hong Kong Science Park, marking a significant milestone in the collaboration between industry leaders from various sectors. This strategic move aims to leverage research findings and creative concepts to create market-ready products and solutions, driving the evolution of the booming global pet industry valued at over USD500 billion. The partnership between APEL and prominent companies is poised to unlock new avenues of growth, fostering an atmosphere of innovation in Hong Kong’s entrepreneurial landscape and sparking economic revitalization.
Emphasizing the importance of technological innovation, Ms. Lillian Cheong, Under Secretary for Innovation, Technology, and Industry of the Hong Kong Special Administrative Region, underscored the government’s commitment to advancing research in life and health technology. Hong Kong’s unique position as a nexus of global connectivity and the unwavering support from the Mainland China government creates a fertile ground for groundbreaking scientific discoveries to translate into tangible products. Initiatives like the establishment of life and health technology research institutes and the InnoLife Healthtech Hub are pivotal in nurturing the growth of local tech enterprises and propelling Hong Kong towards high-quality development.
Dr. Grace Lau, Head of the Institute for Translational Research at the Hong Kong Science and Technology Parks Corporation (HKSTP), commended the inauguration of the APEL Laboratory as a testament to the successful conversion of research and technology breakthroughs into commercially viable products. With a vision to foster a global biotechnology hub, HKSTP is dedicated to facilitating technology transfer and supporting the commercialization of innovative solutions. The surge in biomedical technology advancements in recent years has attracted a diverse range of enterprises specializing in pharmaceuticals, medical devices, diagnostics, and traditional Chinese medicine, reflecting a vibrant landscape of innovation.
Dr. David Chung, Chairman of APEL, highlighted the company’s rapid evolution in both domestic and international markets, culminating in the establishment of the Biomedical Technology Innovation and Translational Commercial Laboratory at Hong Kong Science Park. APEL’s success in bridging the gap between academia and industry underscores its commitment to excellence in scientific research and business acumen. Bolstered by the robust financial backing of its parent company, Yee Hop Holdings Limited, APEL is well-positioned to spearhead the transformation of pioneering ideas into marketable solutions, driving the commercialization of research and development endeavors towards a brighter future.
» …
rnrn